Tianjin Pharmaceutical Da Ren Tang's Q3 Attributable Jumps 54% in Q3

MT Newswires

Oct 30

Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) attributable profit to owners during the third quarter of the year jumped 54% to 224.6 million yuan from 146.1 million a year earlier, according to a Thursday filing with the Singapore Exchange.

Earnings per share rose to 0.30 yuan per share compared with 0.19 yuan in the comparable period.

Revenue fell 38% year over year to 1.02 billion yuan from 1.65 billion yuan, mainly due to a change in the company's consolidation scope which excluded data of Tianjin Zhongxin Medicine.

The directors proposed to seek approval form shareholders for an interim dividend of 24.5 yuan per share for every ten shares in the company's capital.

Shares of the company were up nearly 3% at the close of trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579118117"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579118117\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579118117?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579118117","market":"sg","top_or_hot":-1,"title":"Tianjin Pharmaceutical Da Ren Tang's Q3 Attributable Jumps 54% in Q3","media":"MT Newswires","content":"<html><body><p> Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) attributable profit to owners during the third quarter of the year jumped 54% to 224.6 million yuan from 146.1 million a year earlier, according to a Thursday filing with the Singapore Exchange.</p><p>Earnings per share rose to 0.30 yuan per share compared with 0.19 yuan in the comparable period.</p><p>Revenue fell 38% year over year to 1.02 billion yuan from 1.65 billion yuan, mainly due to a change in the company's consolidation scope which excluded data of Tianjin Zhongxin Medicine.</p><p>The directors proposed to seek approval form shareholders for an interim dividend of 24.5 yuan per share for every ten shares in the company's capital.</p><p>Shares of the company were up nearly 3% at the close of trading on Thursday.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Pharmaceutical Da Ren Tang's Q3 Attributable Jumps 54% in Q3</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Pharmaceutical Da Ren Tang's Q3 Attributable Jumps 54% in Q3\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time\">2025-10-30 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) attributable profit to owners during the third quarter of the year jumped 54% to 224.6 million yuan from 146.1 million a year earlier, according to a Thursday filing with the Singapore Exchange.</p><p>Earnings per share rose to 0.30 yuan per share compared with 0.19 yuan in the comparable period.</p><p>Revenue fell 38% year over year to 1.02 billion yuan from 1.65 billion yuan, mainly due to a change in the company's consolidation scope which excluded data of Tianjin Zhongxin Medicine.</p><p>The directors proposed to seek approval form shareholders for an interim dividend of 24.5 yuan per share for every ten shares in the company's capital.</p><p>Shares of the company were up nearly 3% at the close of trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6506","symbol_name":"制药与医学研究概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2579118117","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579118117","pubTimestamp":1761816869,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tianjin Pharmaceutical Da Ren Tang's  attributable profit to owners during the third quarter of the year jumped 54% to 224.6 million yuan from 146.1 million a year earlier, according to a Thursday filing with the Singapore Exchange.Earnings per share rose to 0.30 yuan per share compared with 0.19 yuan in the comparable period.Revenue fell 38% year over year to 1.02 billion yuan from 1.65 billion yuan, mainly due to a change in the company's consolidation scope which excluded data of Tianjin Zhongxin Medicine.The directors proposed to seek approval form shareholders for an interim dividend of 24.5 yuan per share for every ten shares in the company's capital.Shares of the company were up nearly 3% at the close of trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6506":"制药与医学研究概念","BK6079":"制药","T14.SI":"达仁堂"},"translate_title":"天津医药大仁堂第三季度归属跃升54%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"T14.SI":0.9},"content_text":"Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) attributable profit to owners during the third quarter of the year jumped 54% to 224.6 million yuan from 146.1 million a year earlier, according to a Thursday filing with the Singapore Exchange.Earnings per share rose to 0.30 yuan per share compared with 0.19 yuan in the comparable period.Revenue fell 38% year over year to 1.02 billion yuan from 1.65 billion yuan, mainly due to a change in the company's consolidation scope which excluded data of Tianjin Zhongxin Medicine.The directors proposed to seek approval form shareholders for an interim dividend of 24.5 yuan per share for every ten shares in the company's capital.Shares of the company were up nearly 3% at the close of trading on Thursday.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}